Erasca (ERAS)

Executive Summary

Erasca is a clinical-stage precision oncology company dedicated to eradicating cancer by targeting the RAS/MAPK signaling pathway, which is mutated in approximately 5.5 million new cancer cases annually. Headquartered in San Diego, the company has built a robust pipeline of small molecule inhibitors aimed at various nodes of this pathway. Key programs include naporafenib (pan-RAF inhibitor) in a Phase 3 trial for NRAS-mutant melanoma, ERAS-007 (ERK inhibitor) and ERAS-601 (SHP2 inhibitor) in multiple Phase 1/2 combinations for solid tumors, and ERAS-801 (EGFR inhibitor) for glioblastoma. Erasca's strategy emphasizes rational combination therapies to overcome resistance and improve efficacy. As a public company (NASDAQ: ERAS) with a market capitalization around $6.6 billion, Erasca represents a high-risk, high-reward investment in the oncology space. Recent data readouts and trial initiations in 2025-2026 provide catalysts for near-term value inflection.

Upcoming Catalysts (preview)

• Q2 2026Phase 1/2 Data for ERAS-007 + ERAS-601 in Advanced Solid Tumors60% success
• Q3 2026Phase 1 Data for ERAS-801 in Glioblastoma Multiforme40% success
• Q4 2026Phase 3 Interim Analysis for Naporafenib Combination in NRAS-mutant Melanoma55% success